Paroxysmal Nocturnal Hemoglobinuria Market Epidemiology Report 2025-2035 | Treatment & Rising Incidence

 The 7 major paroxysmal nocturnal hemoglobinuria markets reached a value of US$ 2.9 Billion in 2024. Looking forward, IMARC Group expects the 7MM to reach US$ 6.9 Billion by 2035, exhibiting a growth rate (CAGR) of 8.29% during 2025-2035.



The Paroxysmal Nocturnal Hemoglobinuria (PNH) market is changing the most in 2025 due to treatment options, an increasing patient population, and technological advancements. PNH is a rare blood disorder where the patient suffers from the destruction of red blood cells leading to anemia, fatigue and in some cases, dangerous blood clots. In this article, we take a look at the everchanging market’s trends, study the reasons driving the growing incidence, and focus on the latest technological advances in PNH.

Evolving Trends in PNH Market

The use of Complement Inhibition therapy is one of the most prevalent trends in the PNH market. These include the already established treatments eculizumab and ravulizumab, as well as newer treatments crovalimab (Piasky), pegcetacoplan, and even oral therapies like iptacopan (Fabhalta). The market is shifting to favor more convenient dosing options due to FDA approval of crovalimab in June 2024 and iptacopan in December 2023. Their shift enhances convenience and compliance while reducing the need for hospital visits.

Another trend worth noting is the growth of digital health initiatives. Symptom management and adherence are some of the follow-up care gaps that apps and online platforms such as Ekiva PNH, which was created by Novartis and Dawn Health in April 2024, aim to assist patients with. Greater awareness among health care practitioners as a result of sensitive flow cytometry is also facilitating the earlier detection of PNH clones, even during mild symptomatic phases, thereby broadening the patient base.  

Increasing the Incidence Along With Market Implications  

PNH continues to be a rare condition, however, it is becoming more noticeable in terms of incidence and prevalence. Enhanced diagnostic tools, like flow cytometry, have enabled physicians to identify smaller PNH clones linked with bone marrow disorders which has led to increased detection rates. In conjunction with this, there is also greater survival with effective therapies such as eculizumab, leading to increased prevalence since patients are living longer and are more likely to be on treatment.  

In terms of market perspective, North America and Europe continue to be dominant areas due to the ease of access to advanced therapies and favorable reimbursement policies. The fastest growth, however, is being seen in the Asia Pacific region, particularly China and India. This is driven by increased attention to the treatment of rare diseases and quicker incorporation of PNH therapies within national healthcare frameworks.

Developments Predicted by 2025  

PNH management is witnessing the benefits of innovation as iptacopan and other oral complement inhibitors shift the focus from intravenous therapies to less resource demanding and more flexible treatments . With subcutaneous monoclonal antibodies like crovalimab, dosing convenience improves while clinical trials demonstrate robust preservation of red blood cells .  

Ekiva PNH by Novartis boosts engagement and provides remote symptom management while supporting timely clinical action which expands digital platforms for rare diseases . There is ongoing progress for AI in diagnostic workflows and its analysis of genetic and flow cytometry data for early diagnosis and tailored therapy is still limited .

Request for a sample of this report: https://www.imarcgroup.com/paroxysmal-nocturnal-hemoglobinuria-market/requestsample

Countries Covered:

  • United States
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Japan

Analysis Covered Across Each Country:

  • Historical, current, and future epidemiology scenario
  • Historical, current, and future performance of the paroxysmal nocturnal hemoglobinuria market
  • Historical, current, and future performance of various therapeutic categories in the market
  • Sales of various drugs across the paroxysmal nocturnal hemoglobinuria market
  • Reimbursement scenario in the market
  • In-market and pipeline drugs

This report also provides a detailed analysis of the current paroxysmal nocturnal hemoglobinuria marketed drugs and late-stage pipeline drugs.

In-Market Drugs:

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance

Late-Stage Pipeline Drugs:

  • Drug overview
  • Mechanism of action
  • Regulatory status
  • Clinical trial results
  • Drug uptake and market performance

Competitive Landscape with key players:

The competitive landscape of the paroxysmal nocturnal hemoglobinuria market has been studied in the report with the detailed profiles of the key players operating in the market.

1. Apellis Pharmaceuticals/Swedish Orphan Biovitrum

2. Alexion AstraZencea Rare Disease

3. Alexion AstraZencea Rare Disease

4. Chugai Pharmaceutical/Roche

5. Achillion Pharmaceuticals

6. Novartis Pharmaceuticals

7. Regeneron Pharmaceuticals

8. NovelMed Therapeutics

Ask the Analyst for Customization and Explore the Full Report with TOC: https://www.imarcgroup.com/request?type=report&id=7822&flag=A

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact US:

IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145

Comments

Post a Comment

Popular posts from this blog

Cancer Pain Market Size, Epidemiology, Trends, and Forecast 2025

Image
  The   cancer pain market size   reached a value of USD 1,778.2 Million across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 2,625.8 Million by 2035, exhibiting a growth rate (CAGR) of 3.61% during 2025-2035. The year of 2025 may see the cancer pain market in a raging state, made dynamic from the rise in cancer cases, changing treatment strategies, and significant technological progress. Cancer pain afflicts approximately 53% of all individuals diagnosed with the disease and 64% of those who have the illness at the advanced stage, holding a central position in oncology care. With increasing global cancer incidence, the demand for effective and patient-friendly management of pain has never been higher. A major factor responsible for this expansion is the rising prevalence of cancer worldwide. As the population ages and lifestyle-related risk factors increase, more and more people are getting d...
Read more

Obstructive Sleep Apnea Market Size, Epidemiology, Trends, and Forecast

Image
The 7 major  obstructive sleep apnea markets size  reached a value of USD 794.9 Million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 4,066.7 Million by 2035, exhibiting a growth rate (CAGR) of 16.2% during 2025-2035. Increased global awareness, increasing incidence rates, and technological advancements are largely contributing to the growth of the OSA market in 2025. Sleep apnea refers to periodic arousals from sleep accompanied by cessation of breathing and is a common ailment affecting millions of people across the globe. With increasing awareness about associated health risks such as hypertension, cardiovascular diseases, and diabetes, the demand for diagnosis and treatment on time is rapidly increasing.  One of the leading causes of market growth is the increasing incidences of sleep apnea. In the name of modern lifestyles, with instances of poor sleep hygiene, sedentary behavior, and increased calorie intake, sleep apnea cases are surging a...
Read more

Inflammatory Bowel Disease Market Overview and Trends in 2025

Image
 The 7 major  inflammatory bowel disease markets  reached a value of USD 14.92 Billion in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 20.08 Billion by 2035, exhibiting a growth rate (CAGR) of 2.73% during 2025-2035. Demand surges in the IBD market as the worldwide burden of chronic gastrointestinal disorders continues to increase in 2025. Crohn’s disease and ulcerative colitis are the two most common types of IBD;  they are lifelong diseases characterized by inflammation of the gastrointestinal tract. Increased awareness of the diseases coupled with the development of diagnostic and therapeutic measures is accelerating market growth globally. The focus areas of the market in 2025 are associated with the growing burden of IBD, particularly in developed North American and European countries. But there is a notable increase in prevalence in portions of Asia and even some Latin American countries, which is likely a result of urban lifestyle, dietary h...
Read more